RVW Wealth LLC Makes New $994,000 Investment in Milestone Pharmaceuticals Inc. $MIST

RVW Wealth LLC acquired a new stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,148,260 shares of the company’s stock, valued at approximately $994,000. RVW Wealth LLC owned approximately 0.92% of Milestone Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Guardian Wealth Advisors LLC NC grew its holdings in shares of Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after purchasing an additional 59,200 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Milestone Pharmaceuticals in the first quarter valued at about $397,000. TRU Independence Asset Management 2 LLC acquired a new position in Milestone Pharmaceuticals in the second quarter valued at about $201,000. Renaissance Technologies LLC bought a new stake in Milestone Pharmaceuticals during the first quarter worth about $154,000. Finally, ADAR1 Capital Management LLC bought a new stake in Milestone Pharmaceuticals during the second quarter worth about $134,000. 86.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MIST shares. HC Wainwright reissued a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.40.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock traded down $0.02 during midday trading on Tuesday, reaching $0.76. The company’s stock had a trading volume of 1,389,908 shares, compared to its average volume of 1,815,313. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25. The stock has a market cap of $95.14 million, a PE ratio of -1.11 and a beta of 1.01. Milestone Pharmaceuticals Inc. has a 52 week low of $0.75 and a 52 week high of $3.06. The business has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.33.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. On average, sell-side analysts predict that Milestone Pharmaceuticals Inc. will post -0.84 EPS for the current year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention.